Tunlametinib
- Generic Name
- Tunlametinib
- Indication
适用含抗PD-1/PD-L1治疗失败的NRAS突变的晚期黑色素瘤、结直肠癌患者。
A Prospective, Single-Arm, Open-Label, Single-Center Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib in Subjects With NRAS-Mutant Locally Advanced or Metastatic Thyroid Cancer
- Conditions
- Progressive Locally Advanced or Metastatic Radioactive Iodine Refractory NRAS Mutant Differentiated Thyroid CancerLocally Advanced or Metastatic NRAS Mutant Differentiated, Undifferentiated Thyroid Cancer
- Interventions
- Drug: Tunlametinib plus PD-1
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06970353
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06008106
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06008119
- Locations
- 🇨🇳
Beijing Oncology Hospital, Beijing, Beijing, China
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05331105
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT05263453
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT05233332
- Locations
- 🇨🇳
Beijing Oncology Hospital, Beijing, Beijing, China
HL-085 in NRAS-mutated Advanced Melanoma
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05217303
- Locations
- 🇨🇳
Beijing Oncology Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Study of HL-085 in Patients With Advanced Solid Tumor Tumors
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Kechow Pharma, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04683354
- Locations
- 🇺🇸
Oncology Consultants, Houston, Texas, United States
🇺🇸Comprehensive Cancer Centers, Las Vegas, Nevada, United States
🇺🇸CCARE, San Marcos, California, United States
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03990077
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, China
Phase I Study of HL-085 in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03976050
- Locations
- 🇺🇸
Next Oncology, San Antonio, Texas, United States
🇺🇸Livestrong Cancer Institute, Dell Medical School, The University of Texas at Austin, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.